Citigroup Starts Eli Lilly with a “Buy” Rating; Fiscal Cliff Sequestration Consequences Limited (LLY)
Citigroup initiated coverage on pharmaceutical company Eli Lilly & Co. (LLY) on Friday.
The analysts start LLY off with a “Buy” rating and a price target of $55, a +13% upside to Thursday’s closing price of $48.58
The firm said that they believe the risks of sequestration due to the “fiscal cliff,” meaning a cut to Medicare part D drug spending, would be small for LLY.
Eli Lilly shares were up 17 cents, or +0.35%, in premarket trading on Friday.
The Bottom Line
Shares of Eli Lilly (LLY) have a 4.03% dividend yield, based on last night’s closing stock price of $48.58. The stock has technical support in the $44-$46 price area. If the shares can firm up, we see overhead resistance around the $51-$52 price levels.
Eli Lilly & Co. (LLY) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
FREE Dividend Stock Newsletter
Get the Dividend.com email newsletter to receive:
- A free copy of our acclaimed report, 5 Rules of Winning Dividend Stock Investing
- Free daily investing tips and picks from Dividend.com CEO Paul Rubillo
- Tons of great market analysis and recommendations